Tetsuro Ohishi (Tetsuro Oishi)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Endometrial Cancer

Top Venues

Reproductive medicine and biology

The journal of obstetrics and gynaecology research

Journal of gynecologic oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroaki Komatsu, Masayo Okawa, Kohei Hikino, Yuki Iida, Daiken Osaku, Akiko Kudoh, Jun Chikumi, Shinya Sato, Tetsuro Ohishi, Tasuku Harada
A simplified procedure of nerve-sparing radical hysterectomy. The journal of obstetrics and gynaecology research 48 (3) (2022)
Tomomi Egawa-Takata, Yutaka Ueda, Kimihiko Ito, Kensuke Hori, Tadahiro Shoji, Takayuki Nagasawa, Shin Nishio, Kimio Ushijma, Nishino Koji, Takayuki Enomoto, Akira Kikuchi, Shigeru Honma, Tetsuro Ohishi, Muneaki Shimada, Yuji Takei, Hiroyuki Fujiwara, Hiroshi Tanabe, Aikou Okamoto, Yukihiro Nishio, Tomomi Yamada, Tadashi Kimura
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. Cancer science 113 (5) (2022)
Daiken Osaku, Tetsuro Ohishi, Naoshi Kawamura, Yuki Iida, Hiroaki Komatsu, Akiko Kudoh, Jun Chikumi, Shinya Sato, Tasuku Harada
Differential expression of estrogen receptor subtypes in ovarian high-grade serous carcinoma and clear cell carcinoma. Reproductive medicine and biology 20 (4) (2021)
Takashi Motohashi, Akira Yabuno, Hirofumi Michimae, Tetsuro Ohishi, Miwa Nonaka, Masashi Takano, Shin Nishio, Hiroyuki Fujiwara, Keiichi Fujiwara, Asumi Okumura, Toru Sugiyama, Tsutomu Tabata
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial. Journal of gynecologic oncology 32 (1) (2020)
Mayumi Sawada, Tetsuro Ohishi, Hiroaki Komatsu, Shinya Sato, Jun Chikumi, Michiko Nonaka, Akiko Kudoh, Daiken Osaku, Tasuku Harada
Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer. International journal of clinical oncology 24 (12) (2019)